Tags

Type your tag names separated by a space and hit enter

Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Int J Antimicrob Agents. 2004 Feb; 23(2):129-37.IJ

Abstract

In this randomized, non-blinded study, the efficacy and safety of a 5-day course of moxifloxacin (one 400 mg tablet daily) was compared with that of co-amoxiclav (one 625 mg tablet every 8h) for 7 days, for the treatment of acute exacerbations of chronic bronchitis (AECB). A total of 162 patients with clear signs of an acute exacerbation of chronic bronchitis were enrolled. Of these, 153 could be studied. Seventy-nine patients were randomized in the moxifloxacin arm and 74 in the co-amoxiclav arm of the study. The primary efficacy parameter was clinical response at 14 days in the evaluable population. A clinical success was classified as resolution or improvement of symptoms. Variables used to assess clinical response included wheeze, cough, dyspnoea, sputum volume, rales and ronchi. The success rate in the moxifloxacin group was 88.6% (70 of 79) and that for co-amoxiclav group was 89.2% (66 of 74). At follow-up (28-35 days post-treatment), the continued clinical cure rates were 90.0% (63 of 70) for moxifloxacin and 89.4% (59 of 66) for co-amoxiclav. No significant differences were detected between the two groups. A total of 78 pathogenic bacteria were isolated from the sputum samples of the patients, with Moraxella catarrhalis, Haemophilus influenzae and Streptococcus pneumoniae being the most frequently isolated pathogens. The eradication rate at 14 days in the valid patients was similar for both groups, 90.9% (20 of 22) for the moxifloxacin group and 90.0% (18 of 20) for the co-amoxiclav group. Both drugs were well tolerated with no differences in the drug-related adverse effects or the patients withdrawing because of an adverse event. These results and the good spectrum of antibacterial activity make moxifloxacin a promising and also safe alternative for the empirical treatment of AECB.

Authors+Show Affiliations

Department of Internal Medicine, Infectious Diseases Section, University Hospital, 26500 Rion Patras, Greece. istarakis@yahoo.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15013037

Citation

Starakis, I, et al. "Five-day Moxifloxacin Therapy Compared With 7-day Co-amoxiclav Therapy for the Treatment of Acute Exacerbation of Chronic Bronchitis." International Journal of Antimicrobial Agents, vol. 23, no. 2, 2004, pp. 129-37.
Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents. 2004;23(2):129-37.
Starakis, I., Gogos, C. A., & Bassaris, H. (2004). Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. International Journal of Antimicrobial Agents, 23(2), 129-37.
Starakis I, Gogos CA, Bassaris H. Five-day Moxifloxacin Therapy Compared With 7-day Co-amoxiclav Therapy for the Treatment of Acute Exacerbation of Chronic Bronchitis. Int J Antimicrob Agents. 2004;23(2):129-37. PubMed PMID: 15013037.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. AU - Starakis,I, AU - Gogos,C A, AU - Bassaris,H, PY - 2003/03/11/received PY - 2003/09/22/accepted PY - 2004/3/12/pubmed PY - 2004/4/29/medline PY - 2004/3/12/entrez SP - 129 EP - 37 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 23 IS - 2 N2 - In this randomized, non-blinded study, the efficacy and safety of a 5-day course of moxifloxacin (one 400 mg tablet daily) was compared with that of co-amoxiclav (one 625 mg tablet every 8h) for 7 days, for the treatment of acute exacerbations of chronic bronchitis (AECB). A total of 162 patients with clear signs of an acute exacerbation of chronic bronchitis were enrolled. Of these, 153 could be studied. Seventy-nine patients were randomized in the moxifloxacin arm and 74 in the co-amoxiclav arm of the study. The primary efficacy parameter was clinical response at 14 days in the evaluable population. A clinical success was classified as resolution or improvement of symptoms. Variables used to assess clinical response included wheeze, cough, dyspnoea, sputum volume, rales and ronchi. The success rate in the moxifloxacin group was 88.6% (70 of 79) and that for co-amoxiclav group was 89.2% (66 of 74). At follow-up (28-35 days post-treatment), the continued clinical cure rates were 90.0% (63 of 70) for moxifloxacin and 89.4% (59 of 66) for co-amoxiclav. No significant differences were detected between the two groups. A total of 78 pathogenic bacteria were isolated from the sputum samples of the patients, with Moraxella catarrhalis, Haemophilus influenzae and Streptococcus pneumoniae being the most frequently isolated pathogens. The eradication rate at 14 days in the valid patients was similar for both groups, 90.9% (20 of 22) for the moxifloxacin group and 90.0% (18 of 20) for the co-amoxiclav group. Both drugs were well tolerated with no differences in the drug-related adverse effects or the patients withdrawing because of an adverse event. These results and the good spectrum of antibacterial activity make moxifloxacin a promising and also safe alternative for the empirical treatment of AECB. SN - 0924-8579 UR - https://www.unboundmedicine.com/medline/citation/15013037/Five_day_moxifloxacin_therapy_compared_with_7_day_co_amoxiclav_therapy_for_the_treatment_of_acute_exacerbation_of_chronic_bronchitis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924857903003984 DB - PRIME DP - Unbound Medicine ER -